Skip to content

Identification of
Medicinal Products (IDMP)

Get ready for IDMP

Embrace the digital transformation!

Qdossier supports companies to drive digital transformation within the enterprise by aliging people, processes and tools. Not only to achieve IDMP compliance, but to turn knowledge into an asset with considerable strategic and operational value. Benefit from increased transparency and informed decision making.

We can help you in various ways to prepare for IDMP compliance and beyond. This includes:

  • Gap analyses and readiness assessment
  • Definition of a strategy and roadmap
  • Proof of Concepts for software solutions
  • Definition and implementation of business processes and workflows tuned towards IDMP
  • Data definition and specification of standards and terminologies
  • Data collection, transformation and consolidation

Master data on products, organisations and substances to drive (regulatory) processes

IDMP is a set of ISO standards which enables marketing authorization holders (MAH) to take immediate action to reduce the occurrence of adverse events attributed to substandard batches of substances, package materials, finished products or inferior manufacturers. It also allows determination of adverse events that could be prevented with improvements in the prescribing information. The standards support various other use cases including regulatory processes, inspections, provision of product information from regulator to other stakeholders like e-prescription, traceability in supply chain to detect falsified medicines. The data model is also used as a reference and driver for master data management at both agency and industry side.

Improved signal detection and safeguarding of patients

 Health Authorities (HA) currently collect information across multiple marketing authorization holders who market generic and similar products. Unfortunately, this is hampered since not the same taxonomy is used across products. Furthermore, product’s key characteristics are insufficiently captured in databases and scattered over paper or electronic documents. Objective is to improve the ability to perform analyses by using databases and to increase specificity and selectivity of the analyses by using the same taxonomy within- and across MAHs and HAs. Both changes improve signal detection and allow taking corrective actions to safeguard patients.

More information

Michiel Stam

Michiel Stam
+31 416 707 998
contact

Related consultancy and services

We offer our extensive domain knowledge combined with our passion for digital transformation to build transparent RIM solutions.

Read more

Our specialists understand the business needs; know what structures have been developed; what controlled terminology can be used and how software tools need to be configured to facilitate the Product registration tracking, planning and reporting. 

Read more

Qdossier’s data management team has  experience with different regulatory tracking systems (AG Register, Samarind RMS, Amplexor, Lorenz drugTrack) and understand business context and related processes. 

Read more

More information about
Identification of Medicinal Products (IDMP)?